A group of the world’s biopharma companies are preparing to unveil new data on some of the most closely watched cancer drugs in the pipeline this weekend during the annual meeting of the American Association of Cancer Research in San Diego. And some have begun jostling for the spotlight.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]